Latest Investor Confidence News

Invex Therapeutics Ltd has had its trading suspension lifted following an announcement of new board and officer appointments, signaling a fresh chapter for the biotech company.

Invex Therapeutics has appointed two new non-executive directors and joint company secretaries, signaling a refreshed governance structure alongside a change of company address.

Resolution Minerals has launched a targeted three-hole RC drilling program at its Golden Gate Prospect, aiming to rapidly extend the footprint of its recent gold discovery. This step-out drilling precedes a larger 50-hole campaign, underscoring the project's growing significance in a critical US minerals district.

Ionic Rare Earths has signed a landmark MOU with US Strategic Metals to develop rare earth magnet recycling in Missouri, advancing the US-Australia critical minerals partnership and aiming to reduce reliance on Chinese supply.

Clean TeQ Water has raised A$6 million through a placement supported by major shareholders to fund its expanding international water and resource recovery projects while strengthening its balance sheet.

Clara Resources is set to begin a critical drilling program at its Ashford coking coal project in early 2026, aiming to enhance resource confidence and support a Preliminary Feasibility Study that will refine the project's economic outlook.

Piche Resources has successfully raised approximately AUD 2 million through an oversubscribed placement, attracting strong institutional interest and issuing free attaching options to support its Argentine exploration projects.

Eagle Mountain Mining has requested a voluntary suspension of its ASX-listed securities pending a capital raising announcement, with trading expected to resume by 11 November 2025.

FSI’s FY2025 portfolio posted a modest 5.0% return, trailing the ASX All Ordinaries Index, while maintaining dividend growth and planning a strategic move into pre-IPO investments.

Greenvale Energy Ltd has had its trading suspension lifted immediately following the release of a capital raise announcement, signaling renewed market activity for the energy company.

Chimeric Therapeutics has responded to ASX inquiries regarding the disclosure timing and materiality of new clinical data from its ADVENT-AML trial, emphasizing compliance with continuous disclosure rules and the careful verification of promising patient responses.

Bentley Capital Limited is poised to lift its trading suspension on 6 November 2025 following a key announcement addressing legal costs and regulatory queries.